XORTX Therapeutics Inc (XRTX : TSX-V)
Common Stock
$3.19
CAD
+0.14 (4.59%)
Last updated: 2026-08-31
Get XRTX alerts:
XRTX
XORTX Therapeutics Inc
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+4.59%
1 Month
+13.93%
YTD
-20.25%
Key Statistics
Market Cap
$5.79M
52W High
$9.85
52W Low
$2.42
P/E Ratio
-
50 Day MA
$2.91
200 Day MA
$3.31
Beta
0.08
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 8/31/2026 | $3.20 | $3.20 | $3.19 | $3.19 | $3.19 | 880 |
| 8/27/2026 | $3.33 | $3.33 | $3.05 | $3.05 | $3.05 | 1,925 |
| 8/25/2026 | $3.09 | $3.09 | $3.09 | $3.09 | $3.09 | 100 |
| 8/24/2026 | $2.79 | $2.79 | $2.79 | $2.79 | $2.79 | 200 |
| 8/19/2026 | $2.85 | $2.85 | $2.85 | $2.85 | $2.85 | 1,400 |
| 8/13/2026 | $2.79 | $2.79 | $2.78 | $2.78 | $2.78 | 300 |
| 8/4/2026 | $2.80 | $2.80 | $2.80 | $2.80 | $2.80 | 460 |
| 7/27/2026 | $2.84 | $2.84 | $2.72 | $2.84 | $2.84 | 6,914 |
| 7/14/2026 | $2.95 | $2.95 | $2.95 | $2.95 | $2.95 | 503 |
| 7/8/2026 | $2.93 | $2.93 | $2.88 | $2.88 | $2.88 | 700 |
Analyst Price Targets
Based on analyst covering XRTX
Wall Street analysts forecast XRTX stock price to rise 2439.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$81.00
+2439.2% Upside
Current Price
C$3.19
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on XRTX's historical volatility
30-Day Vol
114.6%
Annualized
90-Day Vol
129.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.39 | C$2.28 – C$5.03 |
| 60 trading days | C$3.59 | C$2.05 – C$6.28 |
| 90 trading days | C$3.81 | C$1.92 – C$7.56 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-2.15M
- Profit Margin
- 0.00%
- ROE (TTM)
- -99.24%
- EPS (Diluted)
- -3.59
- Book Value
- 2.08
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-5
Apr 6, 2026
1-for-9
Nov 14, 2023
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About XRTX
Market movers
Recent TSX-V movers
Top 1-day gainers — updated from our Canadian movers feed.
XRTX.V news timeline
5 articles covering XRTX.V, most recent first
Latest